
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc and OPKO Health Inc to treat growth hormone deficiency in children. The treatment, named Ngenla, is an injectable hormone therapy available in the U.S. from August onwards. Growth hormone deficiency is a rare condition that affects a small number of children, resulting in short stature and delayed puberty without treatment. In a late-stage study, Pfizer's Ngenla demonstrated non-inferiority to their existing growth hormone Genotropin, offering a once-weekly injection option. This approval positions Pfizer to compete with Ascendis Pharma's Skytrofa, another once-weekly growth hormone treatment approved by the FDA in 2021.
Like
Save
Share